Melanoma patients with PD-L1 positive tumors by digital quantification (n=95; 60.9%) showed an improved therapy response upon anti-PD-1 based ICB (BOR=50.5%) as compared to patients with PD-L1 negative tumors (n=61; BOR=32.2%; p=0.026). This evidence concerns the gene CD274 and melanoma.